These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19825473)

  • 21. Botulinum neurotoxin treatment of palmar and plantar hyperhidrosis.
    Weinberg T; Solish N; Murray C
    Dermatol Clin; 2014 Oct; 32(4):505-15. PubMed ID: 25152344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin for hyperhidrosis of areas other than the axillae and palms/soles.
    Glaser DA; Galperin TA
    Dermatol Clin; 2014 Oct; 32(4):517-25. PubMed ID: 25152345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary frontal hyperhidrosis successfully treated with low doses of botulinum toxin A as a useful alternative to surgical treatment.
    Santana-Rodríguez N; Clavo-Varas B; Ponce-González MÁ; Jarabo-Sarceda JR; Pérez-Alonso D; Ruiz-Caballero JA; Olmo-Quintana V; Atallah Yordi N; Fiuza-Pérez MD
    J Dermatolog Treat; 2012 Feb; 23(1):49-51. PubMed ID: 20964567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complications and side-effects of botulinum toxin A.
    Schaffner R; Kreyden OP
    Curr Probl Dermatol; 2002; 30():141-8. PubMed ID: 12471708
    [No Abstract]   [Full Text] [Related]  

  • 25. The protein load of therapeutic botulinum toxins.
    Pickett A; O'Keeffe R; Panjwani N
    Eur J Neurol; 2007 Apr; 14(4):e11. PubMed ID: 17388970
    [No Abstract]   [Full Text] [Related]  

  • 26. Idiopathic localized crossed (left side of the upper part of the body, right side of the lower part of the body) hyperhidrosis: successful treatment of facial area with botulinum a toxin injection.
    Sanli H; Ekmekci P; Akbostanci MC
    Dermatol Surg; 2004 Apr; 30(4 Pt 1):552-4. PubMed ID: 15056150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is age associated with the development of antibodies against botulinum toxin?
    Aun MV; Chung TM; Santos KS; Battistella LM; Rizzo LV; Kalil J; Giavina-Bianchi P
    Allergol Immunopathol (Madr); 2013; 41(4):276-9. PubMed ID: 23031658
    [No Abstract]   [Full Text] [Related]  

  • 28. Localized unilateral hyperhidrosis and neurofibromatosis type 1: case report of a new association.
    Baskan EB; Karli N; Baykara M; Cikman S; Tunali S
    Dermatology; 2005; 211(3):286-9. PubMed ID: 16205077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repetitive injections of botulinum toxin A continuously increase the duration of efficacy in primary axillary hyperhidrosis: a retrospective analysis in 101 patients.
    Brehmer F; Lockmann A; Grönemeyer LL; Kretschmer L; Schön MP; Thoms KM
    J Dtsch Dermatol Ges; 2015 Aug; 13(8):799-805. PubMed ID: 26176740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duration of efficacy increases with the repetition of botulinum toxin A injections in primary axillary hyperhidrosis: a study in 83 patients.
    Lecouflet M; Leux C; Fenot M; Célerier P; Maillard H
    J Am Acad Dermatol; 2013 Dec; 69(6):960-4. PubMed ID: 24035554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacology and immunology of botulinum neurotoxins.
    Aoki KR
    Int Ophthalmol Clin; 2005; 45(3):25-37. PubMed ID: 15970764
    [No Abstract]   [Full Text] [Related]  

  • 32. Facial hyperhidrosis: best practice recommendations and special considerations.
    Glaser DA; Hebert AA; Pariser DM; Solish N
    Cutis; 2007 May; 79(5 Suppl):29-32. PubMed ID: 17596098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Botulinum toxin in the treatment of focal hyperhidrosis].
    Schnider P; Moraru E; Kittler H; Voller B; Kranz G; Auff E
    Wien Klin Wochenschr; 2001; 113 Suppl 4():36-41. PubMed ID: 15506051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical resistance to three types of botulinum toxin type A in aesthetic medicine.
    Stephan F; Habre M; Tomb R
    J Cosmet Dermatol; 2014 Dec; 13(4):346-8. PubMed ID: 25399628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Palmar and plantar hyperhidrosis: best practice recommendations and special considerations.
    Glaser DA; Hebert AA; Pariser DM; Solish N
    Cutis; 2007 May; 79(5 Suppl):18-28. PubMed ID: 17596097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dilution of botulinum toxin A in lidocaine vs. in normal saline for the treatment of primary axillary hyperhidrosis: a double-blind, randomized, comparative preliminary study.
    Güleç AT
    J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):314-8. PubMed ID: 21492253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Commentary: Botulinum toxin in clinical medicine: part II.
    Benedetto AV
    Clin Dermatol; 2004; 22(1):1-2. PubMed ID: 15158537
    [No Abstract]   [Full Text] [Related]  

  • 38. Antibodies after botulinum toxin A injection into musculus detrusor vesicae: incidence and clinical relevance.
    Hegele A; Frohme C; Varga Z; Olbert P; Kranz J; Hofmann R
    Urol Int; 2011; 87(4):439-44. PubMed ID: 22004911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature.
    Vergilis-Kalner IJ
    J Drugs Dermatol; 2011 Sep; 10(9):1013-5. PubMed ID: 22052270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Commentary: Efficacy and safety of a novel botulinum toxin topical gel.
    West TB
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2119-20. PubMed ID: 21244565
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.